Advertisement

Topics

Celltrion’s Biosimilar Rituximab First In Line For FDA Review

00:30 EDT 3 Jul 2017 | SCRIP

After launching its biosimilar infliximab Inflectra in the US late last year, Celltrion is targeting a leading position in oncology...

      

Related Stories

 

Original Article: Celltrion’s Biosimilar Rituximab First In Line For FDA Review

NEXT ARTICLE

More From BioPortfolio on "Celltrion’s Biosimilar Rituximab First In Line For FDA Review"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...